TY  - JOUR
T1  - Youden Index and Optimal Cut-Point Estimated from Observations Affected by a Lower Limit of Detection
A1  - Ruopp, Marcus D.
A1  - Perkins, Neil J.
A1  - Whitcomb, Brian W.
A1  - Schisterman, Enrique F.
Y1  - 2008/06//
KW  - epiblast
KW  - gfp fusion
KW  - histone h2b-
KW  - icm
KW  - lineage specification
KW  - live imaging
KW  - mouse blastocyst
KW  - pdgfr {$α$}
KW  - primitive endoderm
JF  - Biometrical Journal
VL  - 50
IS  - 3
SP  - 419
EP  - 430
SN  - 6176321972
DO  - 10.1002/bimj.200710415
UR  - http://doi.wiley.com/10.1002/bimj.200710415
L1  - file:///Users/angelicacendales/Documents/Cirugía General/Colon y Recto/Sarcopenia/Analisis estadistico/Youden Index and Optimal Cut-Point Estimated from Observations Affected by a Lower Limit of Detection.pdf
N2  - With the effectiveness of therapeutic agents ever decreasing and the increased incidence of multi-drug resistant pathogens, there is a clear need for administration of more potent, potentially more toxic, drugs. Alternatively, biopharmaceuticals may hold potential but require specialised protection from premature in vivo degradation. Thus, a paralleled need for specialised drug delivery systems has arisen. Although cell-mediated drug delivery is not a completely novel concept, the few applications described to date are not yet ready for in vivo application, for various reasons such as drug-induced carrier cell death, limited control over the site and timing of drug release and/or drug degradation by the host immune system. Here, we present our hypothesis for a new drug delivery system, which aims to negate these limitations. We propose transport of nanoparticle-encapsulated drugs inside autologous macrophages polarised to M1 phenotype for high mobility and treated to induce transient phagosome maturation arrest. In addition, we propose a significant shift of existing paradigms in the study of host-microbe interactions, in order to study microbial host immune evasion and dissemination patterns for their therapeutic utilisation in the context of drug delivery. We describe a system in which microbial strategies may be adopted to facilitate absolute control over drug delivery, and without sacrificing the host carrier cells. We provide a comprehensive summary of the lessons we can learn from microbes in the context of drug delivery and discuss their feasibility for in vivo therapeutic application. We then describe our proposed “synthetic microbe drug delivery system” in detail. In our opinion, this multidisciplinary approach may hold the solution to effective, controlled drug delivery.
ER  - 
TY  - JOUR
T1  - Alterations in Muscle Attenuation following Detraining and Retraining in Resistance-Trained Older Adults
A1  - Taaffe, Dennis R.
A1  - Henwood, Tim R.
A1  - Nalls, Michael A.
A1  - Walker, Duncan G.
A1  - Lang, Thomas F.
A1  - Harris, Tamara B.
Y1  - 2009///
KW  - epiblast
KW  - gfp fusion
KW  - histone h2b-
KW  - icm
KW  - lineage specification
KW  - live imaging
KW  - mouse blastocyst
KW  - pdgfr α
KW  - primitive endoderm
JF  - Gerontology
VL  - 55
IS  - 2
SP  - 217
EP  - 223
SN  - 6176321972
DO  - 10.1159/000182084
UR  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf
UR  - https://www.karger.com/Article/FullText/182084
L1  - file:///Users/angelicacendales/Documents/Cirugía General/Colon y Recto/Sarcopenia/Definicion/Alterations in muscle attenuation following detraining and retrainingin resistance trained older adults.pdf
N2  - With the effectiveness of therapeutic agents ever decreasing and the increased incidence of multi-drug resistant pathogens, there is a clear need for administration of more potent, potentially more toxic, drugs. Alternatively, biopharmaceuticals may hold potential but require specialised protection from premature in vivo degradation. Thus, a paralleled need for specialised drug delivery systems has arisen. Although cell-mediated drug delivery is not a completely novel concept, the few applications described to date are not yet ready for in vivo application, for various reasons such as drug-induced carrier cell death, limited control over the site and timing of drug release and/or drug degradation by the host immune system. Here, we present our hypothesis for a new drug delivery system, which aims to negate these limitations. We propose transport of nanoparticle-encapsulated drugs inside autologous macrophages polarised to M1 phenotype for high mobility and treated to induce transient phagosome maturation arrest. In addition, we propose a significant shift of existing paradigms in the study of host-microbe interactions, in order to study microbial host immune evasion and dissemination patterns for their therapeutic utilisation in the context of drug delivery. We describe a system in which microbial strategies may be adopted to facilitate absolute control over drug delivery, and without sacrificing the host carrier cells. We provide a comprehensive summary of the lessons we can learn from microbes in the context of drug delivery and discuss their feasibility for in vivo therapeutic application. We then describe our proposed “synthetic microbe drug delivery system” in detail. In our opinion, this multidisciplinary approach may hold the solution to effective, controlled drug delivery.
ER  -